LV13641B - Immunostimulatory oligonucleotide multimers - Google Patents

Immunostimulatory oligonucleotide multimers Download PDF

Info

Publication number: LV13641B
Authority: LV; Latvia
Prior art keywords: tcg; immunomer; oligonucleotide according; deoxy; immunostimulatory
Prior art date: 2004-06-15

Application number

LVP-07-03A

Other languages

English (en)

Inventor

Sudhir Agrawal

Ekambar Kandimalla

Dong Yu

Original Assignee

Idera Pharmaceuticals Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2004-06-15

Filing date

2007-01-15

Publication date

2008-07-20

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35600219&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LV13641(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2007-01-15 Application filed by Idera Pharmaceuticals Inc filed Critical Idera Pharmaceuticals Inc

2008-07-20 Publication of LV13641B publication Critical patent/LV13641B/en

Links

108091034117 Oligonucleotide Proteins 0.000 title claims abstract description 113
230000003308 immunostimulating effect Effects 0.000 title claims abstract description 60
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 claims description 50
239000000203 mixture Substances 0.000 claims description 28
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 25
208000006673 asthma Diseases 0.000 claims description 24
241000251539 Vertebrata <Metazoa> Species 0.000 claims description 21
201000010099 disease Diseases 0.000 claims description 18
239000002773 nucleotide Substances 0.000 claims description 17
125000003729 nucleotide group Chemical group 0.000 claims description 15
244000052769 pathogen Species 0.000 claims description 15
108090000623 proteins and genes Proteins 0.000 claims description 15
208000023275 Autoimmune disease Diseases 0.000 claims description 14
206010028980 Neoplasm Diseases 0.000 claims description 14
201000011510 cancer Diseases 0.000 claims description 13
230000001717 pathogenic effect Effects 0.000 claims description 13
230000028993 immune response Effects 0.000 claims description 12
239000000443 aerosol Substances 0.000 claims description 11
239000003889 eye drop Substances 0.000 claims description 11
230000000699 topical effect Effects 0.000 claims description 11
206010020751 Hypersensitivity Diseases 0.000 claims description 10
239000007933 dermal patch Substances 0.000 claims description 10
239000003814 drug Substances 0.000 claims description 10
208000026935 allergic disease Diseases 0.000 claims description 9
230000007815 allergy Effects 0.000 claims description 9
230000000295 complement effect Effects 0.000 claims description 9
208000037883 airway inflammation Diseases 0.000 claims description 8
208000035475 disorder Diseases 0.000 claims description 7
239000002324 mouth wash Substances 0.000 claims description 7
229940051866 mouthwash Drugs 0.000 claims description 7
208000017520 skin disease Diseases 0.000 claims description 7
239000003221 ear drop Substances 0.000 claims description 6
208000027866 inflammatory disease Diseases 0.000 claims description 6
239000008194 pharmaceutical composition Substances 0.000 claims description 6
238000009472 formulation Methods 0.000 claims description 2
108020004707 nucleic acids Proteins 0.000 abstract description 26
102000039446 nucleic acids Human genes 0.000 abstract description 26
150000007523 nucleic acids Chemical class 0.000 abstract description 25
230000004048 modification Effects 0.000 description 49
238000012986 modification Methods 0.000 description 49
102100025137 Early activation antigen CD69 Human genes 0.000 description 34
101000934374 Homo sapiens Early activation antigen CD69 Proteins 0.000 description 34
125000001369 canonical nucleoside group Chemical group 0.000 description 29
238000000034 method Methods 0.000 description 28
239000000427 antigen Substances 0.000 description 27
108091007433 antigens Proteins 0.000 description 27
102000036639 antigens Human genes 0.000 description 27
CTMZLDSMFCVUNX-VMIOUTBZSA-N cytidylyl-(3'->5')-guanosine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@H](OP(O)(=O)OC[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C3=C(C(N=C(N)N3)=O)N=C2)O)[C@@H](CO)O1 CTMZLDSMFCVUNX-VMIOUTBZSA-N 0.000 description 27
150000001875 compounds Chemical class 0.000 description 26
241000282414 Homo sapiens Species 0.000 description 22
230000015572 biosynthetic process Effects 0.000 description 22
125000005647 linker group Chemical group 0.000 description 22
229910052739 hydrogen Inorganic materials 0.000 description 21
239000001257 hydrogen Substances 0.000 description 21
238000003786 synthesis reaction Methods 0.000 description 21
PFCLMNDDPTZJHQ-XLPZGREQSA-N 2-amino-7-[(2r,4s,5r)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-1h-pyrrolo[2,3-d]pyrimidin-4-one Chemical compound C1=CC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](CO)O1 PFCLMNDDPTZJHQ-XLPZGREQSA-N 0.000 description 20
239000002777 nucleoside Substances 0.000 description 20
RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 description 20
PEDCQBHIVMGVHV-UHFFFAOYSA-N glycerol group Chemical group OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 18
230000000694 effects Effects 0.000 description 16
150000003833 nucleoside derivatives Chemical class 0.000 description 16
UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 15
102000004127 Cytokines Human genes 0.000 description 15
108090000695 Cytokines Proteins 0.000 description 15
108020004414 DNA Proteins 0.000 description 14
241000699670 Mus sp. Species 0.000 description 14
108010047761 Interferon-alpha Proteins 0.000 description 13
102000006992 Interferon-alpha Human genes 0.000 description 13
OHDXDNUPVVYWOV-UHFFFAOYSA-N n-methyl-1-(2-naphthalen-1-ylsulfanylphenyl)methanamine Chemical compound CNCC1=CC=CC=C1SC1=CC=CC2=CC=CC=C12 OHDXDNUPVVYWOV-UHFFFAOYSA-N 0.000 description 13
NYHBQMYGNKIUIF-UUOKFMHZSA-N Guanosine Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O NYHBQMYGNKIUIF-UUOKFMHZSA-N 0.000 description 12
238000003556 assay Methods 0.000 description 12
150000004713 phosphodiesters Chemical class 0.000 description 12
VGONTNSXDCQUGY-UHFFFAOYSA-N desoxyinosine Natural products C1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 VGONTNSXDCQUGY-UHFFFAOYSA-N 0.000 description 10
229940037003 alum Drugs 0.000 description 9
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 9
239000002953 phosphate buffered saline Substances 0.000 description 9
239000002718 pyrimidine nucleoside Substances 0.000 description 9
239000002342 ribonucleoside Substances 0.000 description 9
230000004044 response Effects 0.000 description 8
238000011282 treatment Methods 0.000 description 8
VGONTNSXDCQUGY-RRKCRQDMSA-N 2'-deoxyinosine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(N=CNC2=O)=C2N=C1 VGONTNSXDCQUGY-RRKCRQDMSA-N 0.000 description 7
CKZJTNZSBMVFSU-UBKIQSJTSA-N 4-amino-5-hydroxy-1-[(2r,4s,5r)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidin-2-one Chemical class C1=C(O)C(N)=NC(=O)N1[C@@H]1O[C@H](CO)[C@@H](O)C1 CKZJTNZSBMVFSU-UBKIQSJTSA-N 0.000 description 7
KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 7
102100035254 Sodium- and chloride-dependent GABA transporter 3 Human genes 0.000 description 7
101710104417 Sodium- and chloride-dependent GABA transporter 3 Proteins 0.000 description 7
102000002689 Toll-like receptor Human genes 0.000 description 7
108020000411 Toll-like receptor Proteins 0.000 description 7
239000002671 adjuvant Substances 0.000 description 7
NAGJZTKCGNOGPW-UHFFFAOYSA-K dioxido-sulfanylidene-sulfido-$l^{5}-phosphane Chemical compound [O-]P([O-])([S-])=S NAGJZTKCGNOGPW-UHFFFAOYSA-K 0.000 description 7
208000015181 infectious disease Diseases 0.000 description 7
238000004519 manufacturing process Methods 0.000 description 7
230000001225 therapeutic effect Effects 0.000 description 7
-1 CpG nucleic acid Chemical class 0.000 description 6
CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 6
IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 6
239000000370 acceptor Substances 0.000 description 6
239000013566 allergen Substances 0.000 description 6
210000004027 cell Anatomy 0.000 description 6
238000002794 lymphocyte assay Methods 0.000 description 6
125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 6
210000000952 spleen Anatomy 0.000 description 6
241000894006 Bacteria Species 0.000 description 5
201000009961 allergic asthma Diseases 0.000 description 5
229910052799 carbon Inorganic materials 0.000 description 5
210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 5
150000003834 purine nucleoside derivatives Chemical class 0.000 description 5
230000028327 secretion Effects 0.000 description 5
239000000126 substance Substances 0.000 description 5
UHDGCWIWMRVCDJ-UHFFFAOYSA-N 1-beta-D-Xylofuranosyl-NH-Cytosine Natural products O=C1N=C(N)C=CN1C1C(O)C(O)C(CO)O1 UHDGCWIWMRVCDJ-UHFFFAOYSA-N 0.000 description 4
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical group N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
MIKUYHXYGGJMLM-GIMIYPNGSA-N Crotonoside Natural products C1=NC2=C(N)NC(=O)N=C2N1[C@H]1O[C@@H](CO)[C@H](O)[C@@H]1O MIKUYHXYGGJMLM-GIMIYPNGSA-N 0.000 description 4
UHDGCWIWMRVCDJ-PSQAKQOGSA-N Cytidine Natural products O=C1N=C(N)C=CN1[C@@H]1[C@@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-PSQAKQOGSA-N 0.000 description 4
NYHBQMYGNKIUIF-UHFFFAOYSA-N D-guanosine Natural products C1=2NC(N)=NC(=O)C=2N=CN1C1OC(CO)C(O)C1O NYHBQMYGNKIUIF-UHFFFAOYSA-N 0.000 description 4
108090000978 Interleukin-4 Proteins 0.000 description 4
108090001005 Interleukin-6 Proteins 0.000 description 4
102000004889 Interleukin-6 Human genes 0.000 description 4
241000699666 Mus <mouse, genus> Species 0.000 description 4
230000004913 activation Effects 0.000 description 4
150000008209 arabinosides Chemical class 0.000 description 4
210000004369 blood Anatomy 0.000 description 4
239000008280 blood Substances 0.000 description 4
UHDGCWIWMRVCDJ-ZAKLUEHWSA-N cytidine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-ZAKLUEHWSA-N 0.000 description 4
OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 4
229940029575 guanosine Drugs 0.000 description 4
150000002402 hexoses Chemical class 0.000 description 4
238000009169 immunotherapy Methods 0.000 description 4
238000010348 incorporation Methods 0.000 description 4
239000003446 ligand Substances 0.000 description 4
MRWXACSTFXYYMV-FDDDBJFASA-N nebularine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC=C2N=C1 MRWXACSTFXYYMV-FDDDBJFASA-N 0.000 description 4
125000003835 nucleoside group Chemical group 0.000 description 4
239000002212 purine nucleoside Substances 0.000 description 4
229960005486 vaccine Drugs 0.000 description 4
PHNDUXLWAVSUAL-SHYZEUOFSA-N 1-[(2r,4s,5r)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-4-sulfanylidenepyrimidin-2-one Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=S)C=C1 PHNDUXLWAVSUAL-SHYZEUOFSA-N 0.000 description 3
YKBGVTZYEHREMT-KVQBGUIXSA-N 2'-deoxyguanosine Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](CO)O1 YKBGVTZYEHREMT-KVQBGUIXSA-N 0.000 description 3
YKBGVTZYEHREMT-UHFFFAOYSA-N 2'-deoxyguanosine Natural products C1=2NC(N)=NC(=O)C=2N=CN1C1CC(O)C(CO)O1 YKBGVTZYEHREMT-UHFFFAOYSA-N 0.000 description 3
IQFYYKKMVGJFEH-BIIVOSGPSA-N 2'-deoxythymidine Natural products O=C1NC(=O)C(C)=CN1[C@@H]1O[C@@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-BIIVOSGPSA-N 0.000 description 3
CKTSBUTUHBMZGZ-SHYZEUOFSA-N 2'‐deoxycytidine Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 CKTSBUTUHBMZGZ-SHYZEUOFSA-N 0.000 description 3
SCVJRXQHFJXZFZ-KVQBGUIXSA-N 2-amino-9-[(2r,4s,5r)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-3h-purine-6-thione Chemical compound C1=2NC(N)=NC(=S)C=2N=CN1[C@H]1C[C@H](O)[C@@H](CO)O1 SCVJRXQHFJXZFZ-KVQBGUIXSA-N 0.000 description 3
125000002103 4,4'-dimethoxytriphenylmethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)(C1=C([H])C([H])=C(OC([H])([H])[H])C([H])=C1[H])C1=C([H])C([H])=C(OC([H])([H])[H])C([H])=C1[H] 0.000 description 3
108091023037 Aptamer Proteins 0.000 description 3
238000011740 C57BL/6 mouse Methods 0.000 description 3
108010041986 DNA Vaccines Proteins 0.000 description 3
229940021995 DNA vaccine Drugs 0.000 description 3
CKTSBUTUHBMZGZ-UHFFFAOYSA-N Deoxycytidine Natural products O=C1N=C(N)C=CN1C1OC(CO)C(O)C1 CKTSBUTUHBMZGZ-UHFFFAOYSA-N 0.000 description 3
238000002965 ELISA Methods 0.000 description 3
102100026720 Interferon beta Human genes 0.000 description 3
108090000467 Interferon-beta Proteins 0.000 description 3
108010002616 Interleukin-5 Proteins 0.000 description 3
108091081548 Palindromic sequence Proteins 0.000 description 3
108091093037 Peptide nucleic acid Proteins 0.000 description 3
108010060818 Toll-Like Receptor 9 Proteins 0.000 description 3
102100033117 Toll-like receptor 9 Human genes 0.000 description 3
125000000217 alkyl group Chemical group 0.000 description 3
125000005600 alkyl phosphonate group Chemical group 0.000 description 3
229960004784 allergens Drugs 0.000 description 3
208000028004 allergic respiratory disease Diseases 0.000 description 3
239000002215 arabinonucleoside Substances 0.000 description 3
PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 3
150000001479 arabinose derivatives Chemical class 0.000 description 3
210000003719 b-lymphocyte Anatomy 0.000 description 3
SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 3
IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 3
239000000872 buffer Substances 0.000 description 3
125000004432 carbon atom Chemical group C* 0.000 description 3
229940079593 drug Drugs 0.000 description 3
235000013305 food Nutrition 0.000 description 3
210000000987 immune system Anatomy 0.000 description 3
230000006698 induction Effects 0.000 description 3
201000010659 intrinsic asthma Diseases 0.000 description 3
238000002955 isolation Methods 0.000 description 3
108010045069 keyhole-limpet hemocyanin Proteins 0.000 description 3
238000002844 melting Methods 0.000 description 3
230000008018 melting Effects 0.000 description 3
229910052757 nitrogen Chemical group 0.000 description 3
208000007892 occupational asthma Diseases 0.000 description 3
150000002972 pentoses Chemical group 0.000 description 3
150000008300 phosphoramidites Chemical class 0.000 description 3
102000004196 processed proteins & peptides Human genes 0.000 description 3
108090000765 processed proteins & peptides Proteins 0.000 description 3
102000004169 proteins and genes Human genes 0.000 description 3
102000005962 receptors Human genes 0.000 description 3
108020003175 receptors Proteins 0.000 description 3
229950010550 resiquimod Drugs 0.000 description 3
201000004335 respiratory allergy Diseases 0.000 description 3
230000029058 respiratory gaseous exchange Effects 0.000 description 3
210000002966 serum Anatomy 0.000 description 3
230000001960 triggered effect Effects 0.000 description 3
108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
102000040650 (ribonucleotides)n+m Human genes 0.000 description 2
125000001731 2-cyanoethyl group Chemical group [H]C([H])(*)C([H])([H])C#N 0.000 description 2
108020000948 Antisense Oligonucleotides Proteins 0.000 description 2
206010003557 Asthma exercise induced Diseases 0.000 description 2
206010003645 Atopy Diseases 0.000 description 2
238000011725 BALB/c mouse Methods 0.000 description 2
108020000946 Bacterial DNA Proteins 0.000 description 2
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
102000014914 Carrier Proteins Human genes 0.000 description 2
108010078791 Carrier Proteins Proteins 0.000 description 2
201000004624 Dermatitis Diseases 0.000 description 2
208000004657 Exercise-Induced Asthma Diseases 0.000 description 2
108060003951 Immunoglobulin Proteins 0.000 description 2
108010074328 Interferon-gamma Proteins 0.000 description 2
241001465754 Metazoa Species 0.000 description 2
JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
102000029797 Prion Human genes 0.000 description 2
108091000054 Prion Proteins 0.000 description 2
101150085390 RPM1 gene Proteins 0.000 description 2
206010039085 Rhinitis allergic Diseases 0.000 description 2
108091028664 Ribonucleotide Proteins 0.000 description 2
PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
208000024780 Urticaria Diseases 0.000 description 2
241000726445 Viroids Species 0.000 description 2
241000700605 Viruses Species 0.000 description 2
239000002253 acid Substances 0.000 description 2
ORILYTVJVMAKLC-UHFFFAOYSA-N adamantane Chemical compound C1C(C2)CC3CC1CC2C3 ORILYTVJVMAKLC-UHFFFAOYSA-N 0.000 description 2
239000000809 air pollutant Substances 0.000 description 2
231100001243 air pollutant Toxicity 0.000 description 2
230000000172 allergic effect Effects 0.000 description 2
201000010105 allergic rhinitis Diseases 0.000 description 2
239000003242 anti bacterial agent Substances 0.000 description 2
230000000692 anti-sense effect Effects 0.000 description 2
229940088710 antibiotic agent Drugs 0.000 description 2
239000000074 antisense oligonucleotide Substances 0.000 description 2
238000012230 antisense oligonucleotides Methods 0.000 description 2
238000013459 approach Methods 0.000 description 2
125000003118 aryl group Chemical group 0.000 description 2
208000010668 atopic eczema Diseases 0.000 description 2
230000008901 benefit Effects 0.000 description 2
230000037396 body weight Effects 0.000 description 2
HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
238000011260 co-administration Methods 0.000 description 2
229940104302 cytosine Drugs 0.000 description 2
210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 2
230000003247 decreasing effect Effects 0.000 description 2
238000011161 development Methods 0.000 description 2
239000003085 diluting agent Substances 0.000 description 2
239000003937 drug carrier Substances 0.000 description 2
125000006575 electron-withdrawing group Chemical group 0.000 description 2
239000002158 endotoxin Substances 0.000 description 2
208000024695 exercise-induced bronchoconstriction Diseases 0.000 description 2
238000002474 experimental method Methods 0.000 description 2
239000003517 fume Substances 0.000 description 2
UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 2
238000009396 hybridization Methods 0.000 description 2
125000004435 hydrogen atom Chemical group [H]* 0.000 description 2
125000001165 hydrophobic group Chemical group 0.000 description 2
229960002751 imiquimod Drugs 0.000 description 2
DOUYETYNHWVLEO-UHFFFAOYSA-N imiquimod Chemical compound C1=CC=CC2=C3N(CC(C)C)C=NC3=C(N)N=C21 DOUYETYNHWVLEO-UHFFFAOYSA-N 0.000 description 2
230000002163 immunogen Effects 0.000 description 2
102000018358 immunoglobulin Human genes 0.000 description 2
238000001727 in vivo Methods 0.000 description 2
230000018711 interleukin-13 production Effects 0.000 description 2
230000017307 interleukin-4 production Effects 0.000 description 2
230000022023 interleukin-5 production Effects 0.000 description 2
239000002085 irritant Substances 0.000 description 2
231100000021 irritant Toxicity 0.000 description 2
239000002502 liposome Substances 0.000 description 2
210000002540 macrophage Anatomy 0.000 description 2
239000000463 material Substances 0.000 description 2
238000002483 medication Methods 0.000 description 2
229940035032 monophosphoryl lipid a Drugs 0.000 description 2
238000010172 mouse model Methods 0.000 description 2
125000004433 nitrogen atom Chemical group N* 0.000 description 2
244000045947 parasite Species 0.000 description 2
230000037361 pathway Effects 0.000 description 2
210000005259 peripheral blood Anatomy 0.000 description 2
239000011886 peripheral blood Substances 0.000 description 2
PTMHPRAIXMAOOB-UHFFFAOYSA-L phosphoramidate Chemical compound NP([O-])([O-])=O PTMHPRAIXMAOOB-UHFFFAOYSA-L 0.000 description 2
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
230000035755 proliferation Effects 0.000 description 2
230000009467 reduction Effects 0.000 description 2
BXNMTOQRYBFHNZ-UHFFFAOYSA-N resiquimod Chemical compound C1=CC=CC2=C(N(C(COCC)=N3)CC(C)(C)O)C3=C(N)N=C21 BXNMTOQRYBFHNZ-UHFFFAOYSA-N 0.000 description 2
208000023504 respiratory system disease Diseases 0.000 description 2
239000002336 ribonucleotide Substances 0.000 description 2
125000002652 ribonucleotide group Chemical group 0.000 description 2
238000003118 sandwich ELISA Methods 0.000 description 2
229920006395 saturated elastomer Polymers 0.000 description 2
239000000779 smoke Substances 0.000 description 2
239000007787 solid Substances 0.000 description 2
239000000243 solution Substances 0.000 description 2
210000004988 splenocyte Anatomy 0.000 description 2
238000010186 staining Methods 0.000 description 2
229960005322 streptomycin Drugs 0.000 description 2
UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
208000024891 symptom Diseases 0.000 description 2
WYWHKKSPHMUBEB-UHFFFAOYSA-N tioguanine Chemical compound N1C(N)=NC(=S)C2=C1N=CN2 WYWHKKSPHMUBEB-UHFFFAOYSA-N 0.000 description 2
230000029069 type 2 immune response Effects 0.000 description 2
239000013598 vector Substances 0.000 description 2
239000003981 vehicle Substances 0.000 description 2
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
LOGFVTREOLYCPF-KXNHARMFSA-N (2s,3r)-2-[[(2r)-1-[(2s)-2,6-diaminohexanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxybutanoic acid Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H]1CCCN1C(=O)[C@@H](N)CCCCN LOGFVTREOLYCPF-KXNHARMFSA-N 0.000 description 1
DRHZYJAUECRAJM-DWSYSWFDSA-N (2s,3s,4s,5r,6r)-6-[[(3s,4s,4ar,6ar,6bs,8r,8ar,12as,14ar,14br)-8a-[(2s,3r,4s,5r,6r)-3-[(2s,3r,4s,5r,6s)-5-[(2s,3r,4s,5r)-4-[(2s,3r,4r)-3,4-dihydroxy-4-(hydroxymethyl)oxolan-2-yl]oxy-3,5-dihydroxyoxan-2-yl]oxy-3,4-dihydroxy-6-methyloxan-2-yl]oxy-5-[(3s,5s, Chemical compound O([C@H]1[C@H](O)[C@H](O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O1)O)O[C@H]1CC[C@]2(C)[C@H]3CC=C4[C@@H]5CC(C)(C)CC[C@@]5([C@@H](C[C@@]4(C)[C@]3(C)CC[C@H]2[C@@]1(C=O)C)O)C(=O)O[C@@H]1O[C@H](C)[C@@H]([C@@H]([C@H]1O[C@H]1[C@@H]([C@H](O)[C@@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@](O)(CO)CO3)O)[C@H](O)CO2)O)[C@H](C)O1)O)O)OC(=O)C[C@@H](O)C[C@H](OC(=O)C[C@@H](O)C[C@@H]([C@@H](C)CC)O[C@H]1[C@@H]([C@@H](O)[C@H](CO)O1)O)[C@@H](C)CC)C(O)=O)[C@@H]1OC[C@@H](O)[C@H](O)[C@H]1O DRHZYJAUECRAJM-DWSYSWFDSA-N 0.000 description 1
NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 1
QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
OTDJAMXESTUWLO-UUOKFMHZSA-N 2-amino-9-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)-2-oxolanyl]-3H-purine-6-thione Chemical compound C12=NC(N)=NC(S)=C2N=CN1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OTDJAMXESTUWLO-UUOKFMHZSA-N 0.000 description 1
OVONXEQGWXGFJD-UHFFFAOYSA-N 4-sulfanylidene-1h-pyrimidin-2-one Chemical compound SC=1C=CNC(=O)N=1 OVONXEQGWXGFJD-UHFFFAOYSA-N 0.000 description 1
TVICROIWXBFQEL-UHFFFAOYSA-N 6-(ethylamino)-1h-pyrimidin-2-one Chemical compound CCNC1=CC=NC(=O)N1 TVICROIWXBFQEL-UHFFFAOYSA-N 0.000 description 1
NLLCDONDZDHLCI-UHFFFAOYSA-N 6-amino-5-hydroxy-1h-pyrimidin-2-one Chemical compound NC=1NC(=O)N=CC=1O NLLCDONDZDHLCI-UHFFFAOYSA-N 0.000 description 1
LOSIULRWFAEMFL-UHFFFAOYSA-N 7-deazaguanine Chemical compound O=C1NC(N)=NC2=C1CC=N2 LOSIULRWFAEMFL-UHFFFAOYSA-N 0.000 description 1
ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 1
208000000884 Airway Obstruction Diseases 0.000 description 1
208000035285 Allergic Seasonal Rhinitis Diseases 0.000 description 1
NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonium chloride Substances [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 1
VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
208000031295 Animal disease Diseases 0.000 description 1
102100024222 B-lymphocyte antigen CD19 Human genes 0.000 description 1
208000035143 Bacterial infection Diseases 0.000 description 1
241001674044 Blattodea Species 0.000 description 1
108091003079 Bovine Serum Albumin Proteins 0.000 description 1
101100454807 Caenorhabditis elegans lgg-1 gene Proteins 0.000 description 1
KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 1
BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
102000019034 Chemokines Human genes 0.000 description 1
108010012236 Chemokines Proteins 0.000 description 1
208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 1
102100030886 Complement receptor type 1 Human genes 0.000 description 1
206010010744 Conjunctivitis allergic Diseases 0.000 description 1
108091029430 CpG site Proteins 0.000 description 1
HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 description 1
206010012438 Dermatitis atopic Diseases 0.000 description 1
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
238000012286 ELISA Assay Methods 0.000 description 1
238000008157 ELISA kit Methods 0.000 description 1
206010014950 Eosinophilia Diseases 0.000 description 1
241000588724 Escherichia coli Species 0.000 description 1
208000004262 Food Hypersensitivity Diseases 0.000 description 1
241000233866 Fungi Species 0.000 description 1
102100040870 Glycine amidinotransferase, mitochondrial Human genes 0.000 description 1
101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 description 1
101000727061 Homo sapiens Complement receptor type 1 Proteins 0.000 description 1
101000893303 Homo sapiens Glycine amidinotransferase, mitochondrial Proteins 0.000 description 1
101000763537 Homo sapiens Toll-like receptor 10 Proteins 0.000 description 1
101000831496 Homo sapiens Toll-like receptor 3 Proteins 0.000 description 1
101000669447 Homo sapiens Toll-like receptor 4 Proteins 0.000 description 1
101000669402 Homo sapiens Toll-like receptor 7 Proteins 0.000 description 1
101000611183 Homo sapiens Tumor necrosis factor Proteins 0.000 description 1
206010061218 Inflammation Diseases 0.000 description 1
208000006877 Insect Bites and Stings Diseases 0.000 description 1
102100037850 Interferon gamma Human genes 0.000 description 1
102000003777 Interleukin-1 beta Human genes 0.000 description 1
108090000193 Interleukin-1 beta Proteins 0.000 description 1
ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
229930182816 L-glutamine Natural products 0.000 description 1
241000239218 Limulus Species 0.000 description 1
108090001030 Lipoproteins Proteins 0.000 description 1
102000004895 Lipoproteins Human genes 0.000 description 1
MSFSPUZXLOGKHJ-UHFFFAOYSA-N Muraminsaeure Natural products OC(=O)C(C)OC1C(N)C(O)OC(CO)C1O MSFSPUZXLOGKHJ-UHFFFAOYSA-N 0.000 description 1
241001529936 Murinae Species 0.000 description 1
101100481579 Mus musculus Tlr11 gene Proteins 0.000 description 1
101100481580 Mus musculus Tlr12 gene Proteins 0.000 description 1
102000010168 Myeloid Differentiation Factor 88 Human genes 0.000 description 1
108010077432 Myeloid Differentiation Factor 88 Proteins 0.000 description 1
241000208125 Nicotiana Species 0.000 description 1
235000002637 Nicotiana tabacum Nutrition 0.000 description 1
101710163270 Nuclease Proteins 0.000 description 1
108091028043 Nucleic acid sequence Proteins 0.000 description 1
TTZMPOZCBFTTPR-UHFFFAOYSA-N O=P1OCO1 Chemical compound O=P1OCO1 TTZMPOZCBFTTPR-UHFFFAOYSA-N 0.000 description 1
206010033078 Otitis media Diseases 0.000 description 1
229910019142 PO4 Inorganic materials 0.000 description 1
229930012538 Paclitaxel Natural products 0.000 description 1
101150071746 Pbsn gene Proteins 0.000 description 1
108010013639 Peptidoglycan Proteins 0.000 description 1
102000003992 Peroxidases Human genes 0.000 description 1
108091000080 Phosphotransferase Proteins 0.000 description 1
206010035664 Pneumonia Diseases 0.000 description 1
241000238711 Pyroglyphidae Species 0.000 description 1
PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 1
241001201572 Sarcocystis masoni Species 0.000 description 1
108010090804 Streptavidin Proteins 0.000 description 1
RYYWUUFWQRZTIU-UHFFFAOYSA-N Thiophosphoric acid Chemical group OP(O)(S)=O RYYWUUFWQRZTIU-UHFFFAOYSA-N 0.000 description 1
102100027009 Toll-like receptor 10 Human genes 0.000 description 1
102100024324 Toll-like receptor 3 Human genes 0.000 description 1
102100039360 Toll-like receptor 4 Human genes 0.000 description 1
102100039390 Toll-like receptor 7 Human genes 0.000 description 1
HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
239000007984 Tris EDTA buffer Substances 0.000 description 1
108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
102100040247 Tumor necrosis factor Human genes 0.000 description 1
DRTQHJPVMGBUCF-XVFCMESISA-N Uridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-XVFCMESISA-N 0.000 description 1
229920000392 Zymosan Polymers 0.000 description 1
238000002835 absorbance Methods 0.000 description 1
230000034662 activation of innate immune response Effects 0.000 description 1
125000002252 acyl group Chemical group 0.000 description 1
125000004423 acyloxy group Chemical group 0.000 description 1
230000033289 adaptive immune response Effects 0.000 description 1
125000003545 alkoxy group Chemical group 0.000 description 1
208000002205 allergic conjunctivitis Diseases 0.000 description 1
HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 description 1
150000001413 amino acids Chemical class 0.000 description 1
235000011114 ammonium hydroxide Nutrition 0.000 description 1
238000004458 analytical method Methods 0.000 description 1
238000010171 animal model Methods 0.000 description 1
PYMYPHUHKUWMLA-WDCZJNDASA-N arabinose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-WDCZJNDASA-N 0.000 description 1
208000024998 atopic conjunctivitis Diseases 0.000 description 1
201000008937 atopic dermatitis Diseases 0.000 description 1
230000001363 autoimmune Effects 0.000 description 1
230000001580 bacterial effect Effects 0.000 description 1
208000022362 bacterial infectious disease Diseases 0.000 description 1
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
238000004113 cell culture Methods 0.000 description 1
238000005119 centrifugation Methods 0.000 description 1
230000008859 change Effects 0.000 description 1
238000007385 chemical modification Methods 0.000 description 1
238000006243 chemical reaction Methods 0.000 description 1
230000000973 chemotherapeutic effect Effects 0.000 description 1
235000012000 cholesterol Nutrition 0.000 description 1
238000011284 combination treatment Methods 0.000 description 1
239000002299 complementary DNA Substances 0.000 description 1
239000005289 controlled pore glass Substances 0.000 description 1
238000010411 cooking Methods 0.000 description 1
125000004093 cyano group Chemical group *C#N 0.000 description 1
231100000433 cytotoxic Toxicity 0.000 description 1
230000001472 cytotoxic effect Effects 0.000 description 1
230000004665 defense response Effects 0.000 description 1
238000000432 density-gradient centrifugation Methods 0.000 description 1
239000005547 deoxyribonucleotide Substances 0.000 description 1
125000002637 deoxyribonucleotide group Chemical group 0.000 description 1
150000004985 diamines Chemical class 0.000 description 1
KPUWHANPEXNPJT-UHFFFAOYSA-N disiloxane Chemical class [SiH3]O[SiH3] KPUWHANPEXNPJT-UHFFFAOYSA-N 0.000 description 1
BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
238000010494 dissociation reaction Methods 0.000 description 1
239000012153 distilled water Substances 0.000 description 1
239000000428 dust Substances 0.000 description 1
238000005516 engineering process Methods 0.000 description 1
230000002708 enhancing effect Effects 0.000 description 1
230000002327 eosinophilic effect Effects 0.000 description 1
210000003608 fece Anatomy 0.000 description 1
239000012894 fetal calf serum Substances 0.000 description 1
239000000945 filler Substances 0.000 description 1
238000000684 flow cytometry Methods 0.000 description 1
235000020932 food allergy Nutrition 0.000 description 1
239000007789 gas Substances 0.000 description 1
208000021302 gastroesophageal reflux disease Diseases 0.000 description 1
238000001415 gene therapy Methods 0.000 description 1
125000005843 halogen group Chemical group 0.000 description 1
238000010438 heat treatment Methods 0.000 description 1
125000000623 heterocyclic group Chemical group 0.000 description 1
238000004128 high performance liquid chromatography Methods 0.000 description 1
229940046533 house dust mites Drugs 0.000 description 1
125000004356 hydroxy functional group Chemical group O* 0.000 description 1
125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
230000036039 immunity Effects 0.000 description 1
229940072221 immunoglobulins Drugs 0.000 description 1
238000000338 in vitro Methods 0.000 description 1
238000011534 incubation Methods 0.000 description 1
230000004054 inflammatory process Effects 0.000 description 1
238000002347 injection Methods 0.000 description 1
239000007924 injection Substances 0.000 description 1
239000002917 insecticide Substances 0.000 description 1
238000009830 intercalation Methods 0.000 description 1
230000004068 intracellular signaling Effects 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
229910052740 iodine Inorganic materials 0.000 description 1
239000011630 iodine Substances 0.000 description 1
239000004816 latex Substances 0.000 description 1
229920000126 latex Polymers 0.000 description 1
210000000265 leukocyte Anatomy 0.000 description 1
150000002632 lipids Chemical class 0.000 description 1
229920006008 lipopolysaccharide Polymers 0.000 description 1
239000007788 liquid Substances 0.000 description 1
JCCNYMKQOSZNPW-UHFFFAOYSA-N loratadine Chemical compound C1CN(C(=O)OCC)CCC1=C1C2=NC=CC=C2CCC2=CC(Cl)=CC=C21 JCCNYMKQOSZNPW-UHFFFAOYSA-N 0.000 description 1
210000004698 lymphocyte Anatomy 0.000 description 1
238000001840 matrix-assisted laser desorption--ionisation time-of-flight mass spectrometry Methods 0.000 description 1
238000005259 measurement Methods 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 description 1
XULSCZPZVQIMFM-IPZQJPLYSA-N odevixibat Chemical compound C12=CC(SC)=C(OCC(=O)N[C@@H](C(=O)N[C@@H](CC)C(O)=O)C=3C=CC(O)=CC=3)C=C2S(=O)(=O)NC(CCCC)(CCCC)CN1C1=CC=CC=C1 XULSCZPZVQIMFM-IPZQJPLYSA-N 0.000 description 1
235000019645 odor Nutrition 0.000 description 1
229940046166 oligodeoxynucleotide Drugs 0.000 description 1
238000002515 oligonucleotide synthesis Methods 0.000 description 1
150000002894 organic compounds Chemical class 0.000 description 1
230000001590 oxidative effect Effects 0.000 description 1
229960001592 paclitaxel Drugs 0.000 description 1
239000003973 paint Substances 0.000 description 1
230000003071 parasitic effect Effects 0.000 description 1
229940056360 penicillin g Drugs 0.000 description 1
239000002304 perfume Substances 0.000 description 1
108040007629 peroxidase activity proteins Proteins 0.000 description 1
235000020030 perry Nutrition 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
239000010452 phosphate Substances 0.000 description 1
102000020233 phosphotransferase Human genes 0.000 description 1
230000037081 physical activity Effects 0.000 description 1
239000013612 plasmid Substances 0.000 description 1
229920000642 polymer Polymers 0.000 description 1
238000002360 preparation method Methods 0.000 description 1
230000002265 prevention Effects 0.000 description 1
230000000770 proinflammatory effect Effects 0.000 description 1
230000000069 prophylactic effect Effects 0.000 description 1
239000010453 quartz Substances 0.000 description 1
238000011552 rat model Methods 0.000 description 1
238000010992 reflux Methods 0.000 description 1
239000011347 resin Substances 0.000 description 1
229920005989 resin Polymers 0.000 description 1
230000000241 respiratory effect Effects 0.000 description 1
238000004007 reversed phase HPLC Methods 0.000 description 1
150000003839 salts Chemical class 0.000 description 1
229930182490 saponin Natural products 0.000 description 1
150000007949 saponins Chemical class 0.000 description 1
235000017709 saponins Nutrition 0.000 description 1
230000035939 shock Effects 0.000 description 1
VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicon dioxide Inorganic materials O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
201000009890 sinusitis Diseases 0.000 description 1
239000002904 solvent Substances 0.000 description 1
210000004989 spleen cell Anatomy 0.000 description 1
239000007921 spray Substances 0.000 description 1
230000006641 stabilisation Effects 0.000 description 1
238000011105 stabilization Methods 0.000 description 1
239000003381 stabilizer Substances 0.000 description 1
238000007447 staining method Methods 0.000 description 1
230000000707 stereoselective effect Effects 0.000 description 1
239000008229 sterile water for irrigation Substances 0.000 description 1
230000004936 stimulating effect Effects 0.000 description 1
230000000638 stimulation Effects 0.000 description 1
239000012089 stop solution Substances 0.000 description 1
238000007920 subcutaneous administration Methods 0.000 description 1
125000001424 substituent group Chemical group 0.000 description 1
150000003457 sulfones Chemical class 0.000 description 1
238000010189 synthetic method Methods 0.000 description 1
RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
150000003568 thioethers Chemical class 0.000 description 1
229960003087 tioguanine Drugs 0.000 description 1
210000001519 tissue Anatomy 0.000 description 1
125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 1
102000003390 tumor necrosis factor Human genes 0.000 description 1
239000002023 wood Substances 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2013—IL-2
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/60—Sugars; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
- C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/117—Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
- A61N2005/1092—Details
- A61N2005/1098—Enhancing the effect of the particle by an injected agent or implanted device
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/17—Immunomodulatory nucleic acids
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/318—Chemical structure of the backbone where the PO2 is completely replaced, e.g. MMI or formacetal
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/33—Chemical structure of the base
- C12N2310/334—Modified C
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/33—Chemical structure of the base
- C12N2310/336—Modified G
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
- C12N2310/3519—Fusion with another nucleic acid

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Organic Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Immunology (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Genetics & Genomics (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Molecular Biology (AREA)
Epidemiology (AREA)
Biochemistry (AREA)
Biomedical Technology (AREA)
Zoology (AREA)
Biotechnology (AREA)
Microbiology (AREA)
Pulmonology (AREA)
General Engineering & Computer Science (AREA)
Wood Science & Technology (AREA)
Physics & Mathematics (AREA)
Mycology (AREA)
Biophysics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Plant Pathology (AREA)
Gastroenterology & Hepatology (AREA)
Pain & Pain Management (AREA)
Dermatology (AREA)
Rheumatology (AREA)
Birds (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

LVP-07-03A 2004-06-15 2007-01-15 Immunostimulatory oligonucleotide multimers LV13641B (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US57998504P	2004-06-15	2004-06-15
US59936204P	2004-08-06	2004-08-06

Publications (1)

Publication Number	Publication Date
LV13641B true LV13641B (en)	2008-07-20

Family

ID=35600219

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
LVP-07-03A LV13641B (en)	2004-06-15	2007-01-15	Immunostimulatory oligonucleotide multimers

Country Status (19)

Country	Link
US (4)	US20060014713A1 (fr)
EP (2)	EP2901856B1 (fr)
JP (1)	JP4942646B2 (fr)
KR (1)	KR20070028537A (fr)
AU (1)	AU2005257938B2 (fr)
BR (1)	BRPI0512110A (fr)
CA (1)	CA2570786C (fr)
EE (1)	EE200700003A (fr)
ES (1)	ES2645158T3 (fr)
HR (1)	HRP20070012A2 (fr)
HU (1)	HUE036894T2 (fr)
IL (1)	IL179973A0 (fr)
LV (1)	LV13641B (fr)
MA (1)	MA28976B1 (fr)
MX (1)	MXPA06014915A (fr)
NO (1)	NO20070263L (fr)
NZ (1)	NZ552522A (fr)
RU (1)	RU2007101039A (fr)
WO (1)	WO2006002038A2 (fr)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20030026782A1 (en) *	1995-02-07	2003-02-06	Arthur M. Krieg	Immunomodulatory oligonucleotides
US6207646B1 (en) *	1994-07-15	2001-03-27	University Of Iowa Research Foundation	Immunostimulatory nucleic acid molecules
CA2302805A1 (fr) *	1997-09-05	1999-03-11	The Regents Of The University Of California	Utilisation d'oligonucleotides immunostimulants pour la prevention ou la reduction des inflammations a mediation granulocytaire et stimulees par des antigenes
US20030022854A1 (en)	1998-06-25	2003-01-30	Dow Steven W.	Vaccines using nucleic acid-lipid complexes
US6693086B1 (en) *	1998-06-25	2004-02-17	National Jewish Medical And Research Center	Systemic immune activation method using nucleic acid-lipid complexes
KR100917101B1 (ko) *	2000-08-04	2009-09-15	도요 보세키 가부시키가이샤	플렉시블 금속적층체 및 그 제조방법
EP2292632A3 (fr) *	2000-09-26	2012-07-25	Idera Pharmaceuticals, Inc.	Modulation de l'activité immunostimulatrice d'analogues oligonucléotidiques immunostimulateurs par des modifications chimiques de position
US7785610B2 (en) *	2001-06-21	2010-08-31	Dynavax Technologies Corporation	Chimeric immunomodulatory compounds and methods of using the same—III
ES2487645T3 (es) *	2001-06-21	2014-08-22	Dynavax Technologies Corporation	Compuestos inmunomoduladores quiméricos y métodos de uso de los mismos
US7276489B2 (en) *	2002-10-24	2007-10-02	Idera Pharmaceuticals, Inc.	Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5′ ends
AR040996A1 (es) *	2002-08-19	2005-04-27	Coley Pharm Group Inc	Acidos nucleicos inmunoestimuladores
US8158768B2 (en) *	2002-12-23	2012-04-17	Dynavax Technologies Corporation	Immunostimulatory sequence oligonucleotides and methods of using the same
AU2004206820B2 (en) *	2003-01-16	2010-06-10	Idera Pharmaceuticals, Inc.	Modulation of immunostimulatory properties of oligonucleotide-based compounds by utilizing modified immunostimulatory dinucleotides
US7354907B2 (en) *	2003-02-07	2008-04-08	Idera Pharmaceuticals, Inc.	Short immunomodulatory oligonucleotides
KR20060012622A (ko) *	2003-05-16	2006-02-08	하이브리돈, 인코포레이티드	화학요법제와 함께 이뮤노머를 사용하는 상승적 암 치료방법
EP1631576A4 (fr) *	2003-06-11	2010-08-25	Idera Pharmaceuticals Inc	Oligonucleotides d'immunomodulation stabilises
US20050013812A1 (en) *	2003-07-14	2005-01-20	Dow Steven W.	Vaccines using pattern recognition receptor-ligand:lipid complexes
KR101126030B1 (ko) *	2003-07-15	2012-03-19	이데라 파마슈티칼즈, 인코포레이티드	사이토킨 및/또는 화학치료제 또는 방사선 치료와 연계하여면역자극 올리고누클레오티드 및/또는 이뮤노머 화합물을이용하여 면역계를 공동 상승 자극시키는 방법
AU2004275876B2 (en) *	2003-09-25	2011-03-31	Coley Pharmaceutical Gmbh	Nucleic acid-lipophilic conjugates
EP1728863A3 (fr)	2003-10-30	2006-12-20	Coley Pharmaceutical GmbH	Analogues d'oligonucléotides de classe C présentant des propriétés immunostimulatrices accrues
CA2567789A1 (fr) *	2004-06-08	2006-08-03	Coley Pharmaceutical Gmbh	Oligonucleotide abasique utilise en tant que plate-forme support pour un antigene ainsi qu'un agoniste et un antagoniste immunostimulatoire
US7498425B2 (en) *	2004-06-15	2009-03-03	Idera Pharmaceuticals, Inc.	Immunostimulatory oligonucleotide multimers
RU2007101039A (ru) *	2004-06-15	2008-07-20	Айдера Фармасьютикалз	Иммуностимулирующие олигонуклеотидные мультимеры
MY159370A (en) *	2004-10-20	2016-12-30	Coley Pharm Group Inc	Semi-soft-class immunostimulatory oligonucleotides
CN101160401A (zh) *	2005-02-24	2008-04-09	科勒制药集团公司	免疫刺激寡核苷酸
PL2179737T3 (pl)	2005-07-01	2014-01-31	Index Pharmaceuticals Ab	Sposób do modulowania wrażliwości na steroidy
DK2269622T3 (en)	2005-07-01	2014-03-24	Index Pharmaceuticals Ab	CPG OLIGONUCLEOTIDES USED TO INCREASE STEROID ACTIVITY OF A STEROID DEPENDENT PATIENT
WO2007050034A1 (fr)	2005-10-28	2007-05-03	Index Pharmaceuticals Ab	Composition et procede pour la prevention, le traitement et/ou l’attenuation d’une maladie inflammatoire
US7470674B2 (en) *	2005-11-07	2008-12-30	Idera Pharmaceuticals, Inc.	Immunostimulatory properties of oligonucleotide-based compounds comprising modified immunostimulatory dinucleotides
US20080045473A1 (en) *	2006-02-15	2008-02-21	Coley Pharmaceutical Gmbh	Compositions and methods for oligonucleotide formulations
MX2009003398A (es)	2006-09-27	2009-08-12	Coley Pharm Gmbh	Analogos de oligonucleotidos cpg que contienen analogos t hidrofobos con actividad inmunoestimuladora mejorada.
CA2693266C (fr) *	2007-08-01	2015-06-30	Idera Pharmaceuticals, Inc.	Nouveaux agonistes synthetiques de tlr9
PT2411521E (pt)	2009-03-25	2015-04-21	Univ Texas	Composições para estimulação de resistência imunitária inata de mamíferos contra patogénicos
GB201021867D0 (en)	2010-12-23	2011-02-02	Mologen Ag	Non-coding immunomodulatory DNA construct
KR101898177B1 (ko) *	2013-01-08	2018-09-12	이데라 파마슈티칼즈, 인코포레이티드	톨－유사 수용체 기반 면역 반응을 조절하기 위한 면역 조절 올리고누클레오티드 （ｉｒｏ） 화합물
CA2919268C (fr)	2013-07-25	2023-09-05	Exicure, Inc.	Constructions a partir d'acides nucleiques spheriques utilisees en tant qu'agents immunostimulants a des fins prophylactiques et therapeutiques
US10144933B2 (en)	2014-01-15	2018-12-04	Shin Nippon Biomedical Laboratories, Ltd.	Chiral nucleic acid adjuvant having immunity induction activity, and immunity induction activator
WO2015108048A1 (fr)	2014-01-15	2015-07-23	株式会社新日本科学	Adjuvant d'acide nucléique chiral ayant un effet antitumoral et agent antitumoral
US10322173B2 (en)	2014-01-15	2019-06-18	Shin Nippon Biomedical Laboratories, Ltd.	Chiral nucleic acid adjuvant having anti-allergic activity, and anti-allergic agent
TR201908550T4 (tr)	2014-06-04	2019-07-22	Exicure Inc	Profilaktik veya terapötik uygulamalar için lipozomal sferik nükleik asitler tarafından immün modülatörlerin çok değerlikli teslimi.
US10286065B2 (en)	2014-09-19	2019-05-14	Board Of Regents, The University Of Texas System	Compositions and methods for treating viral infections through stimulated innate immunity in combination with antiviral compounds
MX391478B (es) *	2014-10-10	2025-03-21	Idera Pharmaceuticals Inc	Composiciones de agonista de tlr9 e inhibidores de punto de control para usarse en la respuesta inmune contra el cáncer.
US11213593B2 (en)	2014-11-21	2022-01-04	Northwestern University	Sequence-specific cellular uptake of spherical nucleic acid nanoparticle conjugates
LU92821B1 (en)	2015-09-09	2017-03-20	Mologen Ag	Combination comprising immunostimulatory oligonucleotides
GB2542425A (en)	2015-09-21	2017-03-22	Mologen Ag	Means for the treatment of HIV
WO2018039629A2 (fr)	2016-08-25	2018-03-01	Northwestern University	Acides nucléiques sphériques micellaires obtenus à partir de matrices thermosensibles sans trace
MX2019002925A (es)	2016-09-15	2019-09-05	Idera Pharmaceuticals Inc	Modulacion inmune con agonistas de tlr9 para el tratamiento del cancer.
US11696954B2 (en)	2017-04-28	2023-07-11	Exicure Operating Company	Synthesis of spherical nucleic acids using lipophilic moieties
US11433131B2 (en)	2017-05-11	2022-09-06	Northwestern University	Adoptive cell therapy using spherical nucleic acids (SNAs)
US20230061403A1 (en) *	2020-03-09	2023-03-02	Dynavax Technologies Corporation	Shingles vaccines comprising a tlr9 agonist
IL296286A (en) *	2020-03-09	2022-11-01	Dynavax Tech Corp	Active booster immunization against tetanus, diphtheria and pertussis

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5149797A (en)	1990-02-15	1992-09-22	The Worcester Foundation For Experimental Biology	Method of site-specific alteration of rna and production of encoded polypeptides
US5652355A (en)	1992-07-23	1997-07-29	Worcester Foundation For Experimental Biology	Hybrid oligonucleotide phosphorothioates
TW244371B (fr)	1992-07-23	1995-04-01	Tri Clover Inc
US6346614B1 (en) *	1992-07-23	2002-02-12	Hybridon, Inc.	Hybrid oligonucleotide phosphorothioates
US5912332A (en) *	1996-07-26	1999-06-15	Hybridon, Inc.	Affinity-based purification of oligonucleotides using soluble multimeric oligonucleotides
US20020028784A1 (en) *	2000-03-10	2002-03-07	Nest Gary Van	Methods of preventing and treating viral infections using immunomodulatory polynucleotide sequences
EP2292632A3 (fr) *	2000-09-26	2012-07-25	Idera Pharmaceuticals, Inc.	Modulation de l'activité immunostimulatrice d'analogues oligonucléotidiques immunostimulateurs par des modifications chimiques de position
NZ526322A (en) *	2000-12-27	2005-06-24	Dynavax Tech Corp	Immunomodulatory polynucleotides and methods of using the same
ES2487645T3 (es) *	2001-06-21	2014-08-22	Dynavax Technologies Corporation	Compuestos inmunomoduladores quiméricos y métodos de uso de los mismos
WO2003035836A2 (fr) *	2001-10-24	2003-05-01	Hybridon Inc.	Modulation des proprietes immunostimulantes de composes a base d'oligonucleotides par presentation optimale d'extremites 5'
US7276489B2 (en) *	2002-10-24	2007-10-02	Idera Pharmaceuticals, Inc.	Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5′ ends
CA2508985A1 (fr) *	2002-12-23	2004-07-15	Dynavax Technologies Corporation	Composes immunomodulateurs ramifies et leur procedes d'utilisation
AU2004206820B2 (en) *	2003-01-16	2010-06-10	Idera Pharmaceuticals, Inc.	Modulation of immunostimulatory properties of oligonucleotide-based compounds by utilizing modified immunostimulatory dinucleotides
US7354907B2 (en) *	2003-02-07	2008-04-08	Idera Pharmaceuticals, Inc.	Short immunomodulatory oligonucleotides
EP1631576A4 (fr) *	2003-06-11	2010-08-25	Idera Pharmaceuticals Inc	Oligonucleotides d'immunomodulation stabilises
US20050004579A1 (en)	2003-06-27	2005-01-06	Schneider M. Bret	Computer-assisted manipulation of catheters and guide wires
KR101126030B1 (ko) *	2003-07-15	2012-03-19	이데라 파마슈티칼즈, 인코포레이티드	사이토킨 및/또는 화학치료제 또는 방사선 치료와 연계하여면역자극 올리고누클레오티드 및/또는 이뮤노머 화합물을이용하여 면역계를 공동 상승 자극시키는 방법
US7498425B2 (en) *	2004-06-15	2009-03-03	Idera Pharmaceuticals, Inc.	Immunostimulatory oligonucleotide multimers
RU2007101039A (ru) *	2004-06-15	2008-07-20	Айдера Фармасьютикалз	Иммуностимулирующие олигонуклеотидные мультимеры

2005
- 2005-06-15 RU RU2007101039/15A patent/RU2007101039A/ru not_active Application Discontinuation
- 2005-06-15 WO PCT/US2005/020911 patent/WO2006002038A2/fr active Application Filing
- 2005-06-15 EE EEP200700003A patent/EE200700003A/xx unknown
- 2005-06-15 BR BRPI0512110-8A patent/BRPI0512110A/pt not_active IP Right Cessation
- 2005-06-15 ES ES15153954.1T patent/ES2645158T3/es not_active Expired - Lifetime
- 2005-06-15 EP EP15153954.1A patent/EP2901856B1/fr not_active Expired - Lifetime
- 2005-06-15 NZ NZ552522A patent/NZ552522A/en unknown
- 2005-06-15 JP JP2007516632A patent/JP4942646B2/ja not_active Expired - Fee Related
- 2005-06-15 AU AU2005257938A patent/AU2005257938B2/en not_active Ceased
- 2005-06-15 CA CA2570786A patent/CA2570786C/fr not_active Expired - Lifetime
- 2005-06-15 KR KR1020077000993A patent/KR20070028537A/ko not_active Withdrawn
- 2005-06-15 MX MXPA06014915A patent/MXPA06014915A/es active IP Right Grant
- 2005-06-15 US US11/153,054 patent/US20060014713A1/en not_active Abandoned
- 2005-06-15 HU HUE15153954A patent/HUE036894T2/hu unknown
- 2005-06-15 EP EP05760552A patent/EP1765417A4/fr not_active Withdrawn
- 2005-06-15 HR HR20070012A patent/HRP20070012A2/xx not_active Application Discontinuation
- 2005-09-22 US US11/234,396 patent/US7405285B2/en not_active Expired - Fee Related
2006
- 2006-12-11 IL IL179973A patent/IL179973A0/en unknown
- 2006-12-29 MA MA29600A patent/MA28976B1/fr unknown
2007
- 2007-01-15 NO NO20070263A patent/NO20070263L/no not_active Application Discontinuation
- 2007-01-15 LV LVP-07-03A patent/LV13641B/en unknown
- 2007-10-23 US US11/876,913 patent/US20080193437A1/en not_active Abandoned
2009
- 2009-09-23 US US12/565,151 patent/US8420615B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
ES2645158T3 (es)	2017-12-04
BRPI0512110A (pt)	2007-10-23
AU2005257938B2 (en)	2010-11-11
WO2006002038A3 (fr)	2008-07-17
HK1211179A1 (en)	2016-05-20
EP2901856B1 (fr)	2017-08-09
EP1765417A4 (fr)	2009-03-25
US20100166736A1 (en)	2010-07-01
KR20070028537A (ko)	2007-03-12
CA2570786C (fr)	2013-05-28
EP2901856A1 (fr)	2015-08-05
NO20070263L (no)	2007-03-09
AU2005257938A1 (en)	2006-01-05
HUE036894T2 (hu)	2018-08-28
US20080193437A1 (en)	2008-08-14
JP2008502688A (ja)	2008-01-31
US7405285B2 (en)	2008-07-29
NZ552522A (en)	2009-04-30
MXPA06014915A (es)	2007-08-20
US20070179103A1 (en)	2007-08-02
US8420615B2 (en)	2013-04-16
MA28976B1 (fr)	2007-11-01
JP4942646B2 (ja)	2012-05-30
IL179973A0 (en)	2007-05-15
EE200700003A (et)	2007-06-15
EP1765417A2 (fr)	2007-03-28
HRP20070012A2 (hr)	2007-10-31
RU2007101039A (ru)	2008-07-20
WO2006002038A2 (fr)	2006-01-05
CA2570786A1 (fr)	2006-01-05
US20060014713A1 (en)	2006-01-19

Publication	Publication Date	Title
AU2005257938B2 (en)	2010-11-11	Immunostimulatory oligonucleotide multimers
US7566702B2 (en)	2009-07-28	Immunostimulatory oligonucleotide multimers
US8946175B1 (en)	2015-02-03	Stabilized immunomodulatory oligonucleotides
JP2007500018A6 (ja)	2007-05-10	安定化免疫調節オリゴヌクレオチド
JP2007530449A (ja)	2007-11-01	小オリゴヌクレオチドに基づく化合物による免疫刺激特性の調節
CA2512934A1 (fr)	2004-08-26	Oligonucleotides immunomodulateurs courts
CN101426370A (zh)	2009-05-06	免疫刺激性寡核苷酸多聚体
HK1211179B (en)	2018-07-06	Immunostimulatory oligonucleotide multimers
MXPA06006506A (en)	2006-12-13	Modulation of immunostimulatory properties by small oligonucleotide-based compounds